New Delhi: India’s Drug Controller General (DCGI) has approved the third phase of Sputnik Light’s bridging trial on the Indian population. Sputnik Lite is a single dose of the Russian vaccine Sputnik, the Covid-1 vaccine.
A recent study published in the medical journal The Lancet found that Sputnik Light showed a .6..6 to 3.7 percent efficacy against Covid-1 against, which is significantly higher than most two-shot vaccines.
The Subject Expert Committee of the Central Drugs Standards Control Organization (CDSCO) in July rejected the need to conduct a third phase trial of the Russian vaccine in the country and refused to approve the emergency use of Sputnik-Lite.
The committee noted that the Sputnik light is similar to Sputnik V’s Component-1 and that the safety and immunogenicity data of the Indian population had already been prepared in an experiment.
The study was conducted on at least 1,000,000 elderly people in Argentina. Sputnik Light reduced hospital admissions by 82.1-87.6 percent of the target population, the study said.
The Russian Direct Investment Fund (RDIF) last year partnered with Dr. Reddy’s Laboratories to test the third phase of the Sputnik V vaccine in India. In April, Sputnik V was approved for an emergency use in India. Reddy 1 Hyderabad May administered the first dose of the vaccine in Hyderabad under a limited pilot.


Read More World News

Keep Reading Latest Breaking News

Source link